Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Buy" from Analysts

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) has received a consensus rating of "Buy" from the eight brokerages that are covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $65.50.

MIRM has been the topic of a number of analyst reports. Wall Street Zen cut Mirum Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Sunday. HC Wainwright reaffirmed a "buy" rating and issued a $73.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday, May 19th. Raymond James Financial reiterated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 13th. Finally, JMP Securities boosted their target price on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a "market outperform" rating in a research note on Friday, May 9th.

Insider Activity

In related news, SVP Jolanda Howe sold 564 shares of Mirum Pharmaceuticals stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $48.25, for a total value of $27,213.00. Following the completion of the sale, the senior vice president directly owned 2,903 shares in the company, valued at $140,069.75. The trade was a 16.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 14.36% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Nuveen LLC purchased a new stake in shares of Mirum Pharmaceuticals in the 1st quarter worth approximately $29,495,000. Federated Hermes Inc. raised its stake in Mirum Pharmaceuticals by 9,440.4% in the first quarter. Federated Hermes Inc. now owns 347,366 shares of the company's stock worth $15,649,000 after buying an additional 343,725 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Mirum Pharmaceuticals during the fourth quarter worth $10,611,000. Nuveen Asset Management LLC lifted its holdings in Mirum Pharmaceuticals by 46.7% during the fourth quarter. Nuveen Asset Management LLC now owns 722,155 shares of the company's stock worth $29,861,000 after buying an additional 229,746 shares during the period. Finally, Frazier Life Sciences Management L.P. boosted its position in Mirum Pharmaceuticals by 3.4% during the 1st quarter. Frazier Life Sciences Management L.P. now owns 6,795,121 shares of the company's stock valued at $306,120,000 after acquiring an additional 224,729 shares in the last quarter.

Mirum Pharmaceuticals Trading Up 1.7%

MIRM stock traded up $0.84 during mid-day trading on Thursday, reaching $49.93. 216,684 shares of the stock traded hands, compared to its average volume of 464,541. Mirum Pharmaceuticals has a one year low of $34.47 and a one year high of $54.23. The stock has a market capitalization of $2.47 billion, a PE ratio of -31.01 and a beta of 0.97. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.04 and a current ratio of 3.22. The business has a 50-day moving average price of $46.46 and a two-hundred day moving average price of $45.52.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative net margin of 20.39% and a negative return on equity of 33.63%. The company had revenue of $111.59 million for the quarter, compared to the consensus estimate of $98.47 million. During the same period in the prior year, the firm posted ($0.54) EPS. The firm's revenue was up 61.2% compared to the same quarter last year. Equities research analysts expect that Mirum Pharmaceuticals will post -1.43 EPS for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.